TLR4 on the surface of scleroderma

BioLineRx Ltd.'s deal with the University of Colorado could give the biotech a disease-modifying therapy for cutaneous fibrosis in patients with diffuse systemic scleroderma.¹ It is still unclear whether the university's toll-like receptor 4 inhibitors will work in other tissues affected by the disease.

There are no marketed disease-modifying drugs for diffuse systemic scleroderma. The diffuse form of the autoimmune disease affects about a third of patients and involves an inflammatory and fibrotic skin component in addition to systemic inflammation and fibrosis of the lungs and other organs...